I believe there is always time for kindness and compassion.
Andre K. D. Liem, M.D., focuses on finding the most appropriate and effective treatment for each cancer patient. Whether this involves an aggressive approach or surveillance, Dr. Liem treats all patients with kindness and compassion. He sees his role as making cancer less burdensome by assisting them with important treatment decisions.
Raised and educated in the Netherlands, Dr. Liem received his medical degree from Radboud University, Nijmegen. He continued medical training at the University of Connecticut and completed his oncology/hematology fellowship at University of California Irvine. He has served as assistant clinical professor of medicine at University of California Los Angeles.
Prior to joining City of Hope, he was a director of clinical research at Pacific Shores Medical Group for over 20 years. Dr. Liem believes that clinical trials are an integral part of cancer treatment as it opens access to promising treatments.
1987, Doctor of Medicine, Radboud University Nijmegen, Nijmegen, Netherlands
1997, Hematology/Oncology, University of California Irvine Medical Center, Orange, CA
1994, Internal Medicine, University of Connecticut Health Center, Farmington, CT
1990, Internal Medicine, Luton & Dunstable Hospital, Luton, United Kingdom
1989, Surgical Internship, General Surgery & Urology,
St. Mary's Hospital, Portsmouth, United Kingdom
2021-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Long Beach, CA
2013-2021, Medical Director, Anticoagulation Center, Greater Newport Physicians, Newport, CA
2009-2014, Tumor Board Chair,
St. Mary Medical Center, Long Beach, CA
2009-2021, IT and EMR Director
2004-2021, Director of Clinical Research Program
1999-2021, Hematologist-Oncologist, Medical Oncology Practice, Pacific Shores Medical Group, Long Beach and Torrance, CA
Barr PM, Saylors G, Spurgeon S, Cheson B, Greenwald D, O’Brien S, Liem A, Mclntyre R, Joshi A, Abella-Dominicis E, Hawkins M, Reddy A, Di Paolo J10, Lee9 H, He J, Hu J, Dreiling L, Friedberg JW. SYK & PI3Kδ pathway inhibition resulted in increased rates of pneumonitis: Implications for developing future small molecule combinations, 2015.
Barr PM, Saylors GB, Spurgeon SEF, Cheson BD, Greenwald DR, O'Brien SM, Liem AKD, McIntyre R, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Wu M, MelchorKhan F, Jin F, Friedberg JW. Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela)in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. J Clin Oncol 32:5s, 2014 (suppl; abstr 7059). 2014. ASCO MEETING ABSTRACTS 7059.
Wainberg ZA, Patel R, DiCarlo B, Park DJ, Kass FC, Liem AKD, Wang H, Martinez D, Hecht JR. Interim results of a phase II study of the mTOR inhibitor everolimus in patients with pretreated metastatic gastric and esophageal adenocarcinoma. ASCO MEETING ABSTRACTS Jan 30, 2012:80
Ward PR, Liem AKD, Wang H, Patel R, Hong-Lung Hu E, Tchekmedyian NS, Wainberg ZA, Hecht JR, Naeim A. Physical function and quality of life in frail and/or elderly metastatic colorectal cancer patients treated with bevacizumab and capecitabine: An exploratory analysis. ASCO MEETING ABSTRACTS Jan 30, 2012:627
Naeim A, Lin LS, Dichmann R, Liem AKD, Chan D, Patel R, Hu EHL, Tchekmedyian NS, Wainberg ZA, Hecht JR. TORI Research Team: F. Kabbinavar , H.J. Wang, and N. Ryba. Phase II study of frontline capecitabine (CAP)and bevacizumab (BEV) in frail and elderly patients with metastatic colorectal cancer (mCRC). American Society of Clinical Oncology, GI symposium Abstr. #1611, 2010.
Saura C, Martin M, Moroose R, Harb W, Liem K, Arena F, Gressler V, Cortés J, Wade M, Powell C, Shapiro M. Safety of neratinib (HKI-272) in combination with capecitabine in patients with solid tumors: a phase 1/2 study. Poster San Antonia Breast Cancer Symposium, 2009.
Tchekmedyian NS, Liem AK, Quan ET, Burtzo DM, Ucar K. Aromatase inhibitor therapy for estrogen receptor positive ovarian cancer. ASCO MEETING ABSTRACTS Jun 16, 2006:15038
Liem AK, Cheng H, Quan E, Ucar K, Al-Jazayrly G, Barton C, Cloo L, Gabert T, Tchekmedyian S. Expanded access single institution clinical program experience with ZD1839 (Iressa ™) for patients with advanced non-small cell lung cancer (NSCLC). Proc. of the American Society of Clinical Oncology, Abstr. #2705, 2002.
Tchekmedyian NS, Liem AKD. A Patient with Metastatic Non-SmallCell Lung Cancer Treated with ZD1839. Case studies in lung cancer, a Physicians’ Education Resource publication, vol.1, no. 9, November 2002.
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Show respect for what you say
Spend enough time with you
Provider listen carefully to you
Know important info medical history
Rate provider 0-10
Provider explain in way you understand
Recommend this provider office
Dr. Liem is an excellent doctor. He shows compassion for patients. He is very knowledgeable. I am sad that he's going to retire. - Verified patient
Dr Liem was very attentive to my health concerns - Verified patient
Dr. Liem is always helpful and a good listener. He truly cares about his patients. - Verified patient